Product Name | Alirocumab |
---|---|
CAS | 1245916-14-6 |
Appearance | A liquid |
Storage condition | Sealed and stored at ≤-30℃, away from light. Avoid freeze-thaw cycles |
Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
---|---|---|---|---|
1 mg | 3-5days | ¥3000.00 | Visible after login | |
5 mg | 3-5days | ¥12500.00 | Visible after login | |
10 mg | 3-5days | ¥20000.00 | Visible after login | |
50 mg | 3-5days | ¥80000.00 | Visible after login | |
100 mg | 3-5days | ¥125000.00 | Visible after login |
Product Name | Alirocumab |
---|---|
CAS | 1245916-14-6 |
Appearance | A liquid |
Storage condition | Sealed and stored at ≤-30℃, away from light. Avoid freeze-thaw cycles |
Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation. Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of PCSK9. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia.